Acute GvHD is a significant complication of allogeneic hematopoietic stem cell transplantation (HCT) and carries a high rate of morbidity and mortality. 1 Chemokines are known to influence the recruitment of activated donor T-lymphocytes to target organs. 2 C-X-C motif chemokine 10 (also known as interferon-γ-inducible protein-10) has been previously reported to be elevated in the serum of adult allogeneic HCT recipients with acute skin GvHD.
3 CXCL10 was also shown to be detected in the epidermis in skin biopsies from patients with acute skin GvHD, but not from gastrointestinal (GI) biopsies from patients with acute GI GvHD. 3 Therefore, CXCL10 is thought to play a role in the pathogenesis of acute skin GvHD by recruiting activated T-lymphocytes to the skin. 4 Studying target organ cytokines in children is challenging due to the invasive nature of skin biopsies, especially as acute GvHD is primarily a clinical diagnosis and biopsies are often unavailable. 5 Recent studies in neonates demonstrated a novel methodology to detect skin cytokines non-invasively, making this an attractive approach in pediatric HCT recipients. 6 We hypothesized that CXCL10 would be detected in children with acute skin GvHD both systemically and locally at the time of onset of the skin rash, similar to the findings in adult HCT recipients with acute skin GvHD. We estimated CXCL10 from the skin with a novel non-invasive epidermal skin patch called D-Squame disc (CuDerm, Dallas, TX, USA), and compared these levels to CXCL10 levels in the plasma obtained at similar time points. We show that CXCL10 levels are elevated in patients with acute skin GvHD at the time of diagnosis from the plasma and epidermis.
Pediatric allogeneic stem cell transplant recipients were enrolled prospectively after informed consent was obtained. Healthy pediatric controls were also recruited on study from the primary care pediatric clinic at our center. Subjects with pre-existing chronic skin conditions, such as acne, eczema or psoriasis were excluded from enrollment. The study was registered under ClinicalTrials.gov under the identifier number NCT02511782.
Skin samples were obtained non-invasively using D-Squame disks, which are made of high clarity polymeric film and have a fully cured medical grade synthetic polyacrylate ester adhesive (Figure 1a) . 7, 8 These disks were placed on a pre-plotted area of the skin of the non-dominant forearm of subjects on study and removed after 2 min. D-Squame disks uniformly sampled a fixed area of stratum corneum, and the adhering corneocytes were analyzed for cytokines. This technique helped in eliminating the need for invasive tissue biopsies and provided a rapid and easy methodology for obtaining useful and relevant biological material for measuring target organ cytokines. These D-Squame disks were used safely in children with latex allergies. In addition, these sampling disks, although having an adhesive, were painless during removal from the skin, unlike known adhesive materials (adhesive tapes, Band-Aids) used in patients.
Skin sample collection included a baseline sample before initiation of preparative regimen, to get an estimate of the patients' epidermal cytokine profile. A second sample was obtained after the conditioning regimen to measure changes in cytokines due to toxicity of chemotherapy or radiation. Following stem cell infusion, samples were collected weekly from pre-defined areas of the skin (either the forearm or wrist) of all subjects until day +100. If any lotions or creams were applied to the skin, a sample was obtained 2 h after the area was washed with soap and water, to avoid cross contamination. During acute skin GvHD, samples were placed on the rash of the upper extremity closest to the designated area of sampling for that week. Plasma was obtained at the same time point as the skin samples in all HCT patients to compare differences in cytokines between the peripheral blood and skin. Patients were followed until day +100 if no acute skin GvHD developed. GvHD was graded using the modified Glucksberg criteria. Skin biopsies were only obtained if clinically indicated and on the discretion of the treating physician. If any patient had evidence of acute skin GvHD, they remained on study until resolution of clinical symptoms. During periods of sepsis or cellulitis of the skin, samples were not collected from the skin or plasma. Once these conditions had resolved, sample collection was resumed. A single skin sample was obtained from healthy pediatric controls to measure baseline cytokine values in unaffected children. Primary end-points of the study were feasibility of using the epidermal patch in the pediatric HCT population and comparison of cytokines from the plasma and skin during acute skin GvHD.
Cytokines were extracted from the D-Squame sampling disks using a buffer made of PBS and 0.25 M saline, and analyzed using a 38-plex human cytokine Milliplex MAP magnetic bead panel (EMD Millipore Corp, Billerica, MA, USA). The cytokines analyzed included IL-1α, IL-1β, IL-1Rα, IL-2,IL-3, IL-4, IL-5, IL-6, IL-8, IL-9, IL-10, IP-10, IL-12p450, IL12-p70, IL-13, IL-15, IL-17A, MCP-1, Macrophage-derived chemokine (MDC), MCP-3, MIP-1α, MIP-1β, sCD40L, TGF-α, TGF-β, EGF, FGF2, FLT-3L, Eotaxin, Fractalkine, G-CSF, GM-CSF, GRO, IFN-α2, IFN-γ and VEGF. Total protein extracted from the sampling disks was quantified using a micro bicinchoninic acid protein assay, and cytokines were normalized to total protein. Plasma was analyzed for CXCL10 by using a human cytokine Milliplex MAP magnetic bead panel (EMD Millipore Corp, Billerica, MA, USA). Statistical analysis was performed by comparing cytokine values between the three groups using a student t-test. A P value of o0.05 was deemed to signify statistical significance.
For purposes of analysis, patients were divided into three groups: patients with acute skin GvHD, patients without skin GvHD and healthy pediatric controls.
Thirty patients were enrolled prospectively on study. Three groups of patients were included in the analysis: patients with acute skin GvHD (n = 10), no skin GvHD (n = 10) and healthy pediatric controls (n = 10). Demographic information of these patients is shown in Table 1 . The median age was 7.7 years (range, 1.5-16.5 years) in patients with acute GvHD, 4.8 years (range, 1.4-14.2 years) in patients without acute GvHD andgrade III acute skin GvHD. Of the patients with acute skin GvHD, 2 patients had concurrent GI GvHD, whereas 3 had skin, liver and GI GvHD. Median time of onset of acute skin GvHD was 26 days (range, 17-47 days) after stem cell infusion.
CXCL10 from the epidermis was found to be elevated in patients with skin GvHD at the time of onset of skin rash when compared to patients without skin GvHD (P = 0.02) (Figure 1b) and healthy pediatric controls (P = 0.03) (Figure 1c ). Plasma levels of CXCL10 were also found to be elevated in patients with acute skin GvHD at the time of GvHD onset when compared to comparable time points in patients who did not develop acute skin GvHD (P o 0.05) (Figure 1d ). Several additional cytokines were analyzed from the plasma and the skin but none of the additional cytokines demonstrated a simultaneous elevation in both skin and plasma. Mean plasma IL-1Rα was significantly decreased in patients with acute skin GvHD (P = 0.013) but was not altered in the epidermis. Mean epidermal MDC was significantly decreased in patients with acute skin GvHD at baseline (P = 0.03) compared to patients without acute skin GvHD but was not altered in the plasma. Mean epidermal IL-2 was significantly elevated at baseline (P = 0.01) but was not altered at baseline from the plasma in patients with acute skin GvHD.
Epidermal innate immunity involves a balance of pro-and anti-inflammatory cytokines and specific APC. Epidermal keratinocytes are known to secrete cytokines (for example, IL-1) in response to stratum corneum damage and help to coordinate the recovery process, thereby serving as the effector cells. 9 Our primary objective was to study epidermal cytokines non-invasively in children with acute skin GvHD. We used a novel methodology of obtaining samples from the epidermis based on prior studies performed in neonates successfully and experienced no challenges with subject enrollment or completion.
IFN-γ-inducible protein-10 (IP-10, CXCL10) is a chemokine secreted from cells stimulated with type I and II interferon and lipopolysaccharides. 10 It is a known chemo-attractant of activated T cells and its expression seen in many Th1-type inflammatory diseases. 11 We chose to study CXCL10 specifically for the following reasons. First, CXCL10 has already been studied in patients with acute skin GvHD and has been detected in skin biopsies, thereby already providing evidence that it is likely to be readily detected locally even with this non-invasive methodology. Second, it has been shown that, after recruitment of activated lymphocytes into the dermis, the CCL27 pathway guides the lymphocytes all the way up to the epidermis. [11] [12] [13] Therefore, the detection of CXCL10 could be feasible even with surface epidermal sampling.
It is important to underscore the exceptionally favorable adverse effect profile of this epidermal patch. This has been prevalent as a tool in dermatologic research for over 20 years and thus far, no known adverse effects related to this patch have been reported. In our patient population, no adverse effects related to the epidermal patch were observed including allergic reactions to the tape, contact dermatitis or pain, making this an easy methodology to use. In addition to being non-invasive, the cost of obtaining an epidermal cytokine sample is $30/patient compared to~$600/patient for an invasive skin biopsy with pathology review.
Some additional cytokine levels were altered either in the plasma or the epidermis in patients with acute skin GvHD but not simultaneously at similar time points. We speculate that this observation might be due to the uniqueness of the target organ cytokine profile, which is different from the plasma cytokine profile of acute skin GvHD. These observations will be studied in a larger group of patients to shed further light into this hypothesis. This study has several limitations. Our sample size is relatively small and this has limited our ability to distinguish between IP-10 levels in the skin and plasma in different grades of acute skin GvHD. As no skin biopsies were obtained clinically by the treating physicians for patients on study, we cannot compare the cytokines obtained from the epidermal tape directly to cytokines from biopsies. Lastly, this methodology only allows for the detection of epidermal cytokines and does not provide insight into dermal cytokine levels, which could significantly influence the biology of acute skin GvHD.
The rapidity, ease, lack of adverse effects and non-invasive nature of D-Squame skin sampling disks is an attractive option in aiding in the diagnosis of acute GvHD in pediatric patients, especially young infants. These disks may be used safely in children with latex allergies and are relatively painless when compared to removal of adhesive tapes from the skin. These may also be used serially in patients for analysis and detection of additional surface cytokines in the future. 
